Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign no...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean medical science Vol. 33; no. 53; pp. e342 - 6
Main Authors Jung, Young Ju, Oh, In-Jae, Kim, Youndong, Jung, Jong Ha, Seok, Minkyoung, Lee, Woochang, Park, Cheol Kyu, Lim, Jung-Hwan, Kim, Young-Chul, Kim, Woo-Sung, Choi, Chang-Min
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Academy of Medical Sciences 31.12.2018
대한의학회
Subjects
Brief Communication
의학일반
Aptamer
Computed Tomography
Lung Nodule
Lung Cancer Screening
Online AccessGet full text
ISSN1011-8934
1598-6357
1598-6357
DOI10.3346/jkms.2018.33.e342

Cover

More Information
Summary:We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ≥ 55 years of age and ≥ 30 pack-years, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. AptoDetect™-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Young Ju Jung and In-Jae Oh contributed equally to this work.
ISSN:1011-8934
1598-6357
1598-6357
DOI:10.3346/jkms.2018.33.e342